Adial Pharmaceuticals (ADIL) Other Operating Expenses (2017 - 2025)
Adial Pharmaceuticals (ADIL) posted Other Operating Expenses of $940790.0 for Q2 2025, down 26.07% sequentially from $1.3 million in Q4 2024, and up 353.65% YoY from $207383.6 in Q2 2024.
Adial Pharmaceuticals (ADIL) Other Operating Expenses (2017 - 2025) Analysis & Trends
Adial Pharmaceuticals has reported Other Operating Expenses for 7 years, with the latest figure at $940790.0 in Q2 2025.
- Quarterly Other Operating Expenses rose 353.65% year-over-year to $940790.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $940790.0 (up 4.33% YoY) and the FY2024 annual result came in at $119886.0, up 125.44% from the prior year.
- Other Operating Expenses fell to $940790.0 in Q2 2025 per ADIL's latest filing, from $1.3 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $2.2 million in Q2 2021 and troughed at -$905087.0 in Q4 2023.
- A 5-year average of $239925.3 and a median of -$85587.0 in 2022 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Other Operating Expenses tumbled 2320.67% in 2023, then surged 353.65% in 2025.
- Over 5 years, Other Operating Expenses stood at $1.5 million in 2021, then tumbled by 102.41% to -$37390.0 in 2022, then sank by 2320.67% to -$905087.0 in 2023, then jumped by 240.61% to $1.3 million in 2024, then fell by 26.07% to $940790.0 in 2025.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $940790.0, $1.3 million, and -$370905.0 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 940,790.00 |
| Dec 31, 2024 | 1.27 Mn |
| Jun 30, 2024 | -370,905.00 |
| Mar 31, 2024 | -560,234.00 |
| Dec 31, 2023 | -905,087.00 |
| Sep 30, 2023 | -403,530.00 |
| Jun 30, 2023 | -114,297.00 |
| Mar 31, 2023 | -341,134.00 |
| Dec 31, 2022 | -37,390.00 |
| Sep 30, 2022 | -85,587.00 |
| Jun 30, 2022 | -66,491.00 |
| Dec 31, 2021 | 1.55 Mn |
| Jun 30, 2021 | 2.24 Mn |
| Dec 31, 2020 | 5.60 Mn |
| Jun 30, 2020 | 833,934.00 |
| Mar 31, 2020 | 973,139.00 |
| Dec 31, 2017 | -134,700.00 |
| Sep 30, 2017 | 73,882.00 |
| Jun 30, 2017 | 22,422.00 |